Table 2 Results regarding data availability and completeness
Data source | Pooled data from 15 European registries collecting information on patients with SpA | |||||
|---|---|---|---|---|---|---|
Pooled data (n=33,948) | Before January 1, 2015 (n=16,207) | From January 1, 2015 (n=21,423) | axSpA (n=21,330) | PsA (n=12,618) | ||
Variables | No of registries with available data | Data completeness, mean % (range)a | Data completeness, mean %a | |||
Demography | ||||||
Age | 15 | 100 (100–100) | 100% | 100% | 100% | 100% |
Sex | 15 | 100 (100–100) | 100% | 100% | 100% | 100% |
Weight | 14 | 67 (7–100) | 71% | 64% | 68% | 65% |
Height | 14 | 64 (13–100) | 65% | 64% | 65% | 63% |
Lifestyle | ||||||
Smoking | 13 | 85 (15–100) | 82% | 88% | 85% | 84% |
Alcohol consumptionb | 4 | 29 (7–76) | 21% | 44% | 26% | 32% |
Disease duration and classification criteria | ||||||
Disease duration (years) | 15 | 92 (53–100) | 96% | 88% | 93% | 90% |
Symptom duration (years) | 9 | 75 (33–100) | 72% | 78% | 75% | 74% |
ASAS criteria | 9 | 46 (5–100) | 47% | 46% | 63% | 16% |
Modified New York criteria | 9 | 38 (5–100) | 40% | 35% | 49% | 17% |
CASPAR criteria | 7 | 27 (6–100) | 29% | 26% | 15% | 48% |
Clinical characteristics at baseline | ||||||
Swollen joint count (28) | 14 | 60 (28–100) | 59% | 61% | 45% | 85% |
Tender joint count (28) | 14 | 56 (28–100) | 53% | 59% | 38% | 85% |
Swollen joint count (66) | 10 | 29 (5–74) | 20% | 37% | 16% | 50% |
Tender joint count (68) | 10 | 31 (6–76) | 21% | 39% | 17% | 54% |
Physician global | 13 | 71 (13–92) | 71% | 71% | 64% | 82% |
Enthesitis (MASES) | 6 | 25 (6–70) | 20% | 29% | 29% | 16% |
Dactylitis (yes/no) | 5 | 33 (10–97) | 40% | 28% | 26% | 46% |
Skin (PASI binary) | 4 | 40 (1–92) | 53% | 31% | 35% | 49% |
Nails (NAPSI binary) | 2 | 44 (27–83) | 44% | 44% | 23% | 92% |
BASMI | 8 | 26 (3–100) | 24% | 27% | 39% | 7% |
Biological or targeted synthetic DMARD treatment | ||||||
Name of b/tsDMARD | 15 | 100 (100–100) | 100% | 100% | 100% | 100% |
Treatment series number | 15 | 100 (100–100) | 100% | 100% | 100% | 100% |
Treatment start date | 15 | 100 (100–100) | 100% | 100% | 100% | 100% |
Treatment stop date | 15 | 53 (5–71) | 69% | 39% | 51% | 56% |
Concomitant medication at baseline | ||||||
Conventional synthetic (cs) DMARD | 14 | 71 (2–100) | 67% | 74% | 68% | 75% |
Methotrexate | 14 | 66 (2–100) | 64% | 68% | 63% | 71% |
Sulfasalazine | 14 | 63 (2–100) | 62% | 65% | 63% | 65% |
Leflunomide | 14 | 62 (2–100) | 60% | 63% | 60% | 64% |
Other csDMARDs | 13 | 65 (2–100) | 60% | 68% | 63% | 67% |
Oral glucocorticoidsc | 11 | 86 (33–100) | - | 86% | 84% | 88% |
NSAIDs | 8 | 56 (16–100) | 42% | 69% | 61% | 46% |
Patient-reported outcomes at baseline | ||||||
BASDAI | 15 | 63 (28–100) | 54% | 71% | 78% | 39% |
BASFI | 11 | 59 (16–100) | 50% | 68% | 74% | 35% |
HAQ | 12 | 68 (14–97) | 63% | 72% | 58% | 83% |
Patient global | 14 | 82 (43–100) | 79% | 85% | 79% | 87% |
Patient fatigue | 8 | 68 (23–90) | 57% | 79% | 71% | 64% |
Patient pain | 13 | 77 (26–100) | 68% | 86% | 74% | 82% |
Laboratory parameters at baseline | ||||||
CRP | 15 | 85 (22–100) | 88% | 83% | 85% | 85% |
ESR | 13 | 84 (46–100) | 85% | 82% | 83% | 85% |
HLA-B27 | 14 | 67 (8–95) | 63% | 71% | 80% | 46% |
Peripheral and extra-musculoskeletal manifestations of spondyloarthritis (ever/never) | ||||||
Enthesitis | 5 | 78 (73–100) | 82% | 75% | 80% | 73% |
Dactylitis | 6 | 80 (4–100) | 91% | 72% | 79% | 81% |
Psoriasis | 12 | 56 (2–100) | 61% | 53% | 60% | 50% |
Uveitis | 11 | 84 (4–100) | 87% | 82% | 83% | 86% |
Inflammatory bowel disease | 11 | 57 (1–100) | 61% | 53% | 60% | 51% |
Comorbidities (ever/never) | ||||||
Cardiovascular | 13 | 65 (10–100) | 63% | 68% | 69% | 59% |
Diabetes | 13 | 55 (7–100) | 53% | 57% | 54% | 57% |
Kidney disease | 12 | 66 (3–100) | 65% | 67% | 69% | 60% |